Forecast

The analysts' average price target is €8.48 (+44.46%). The median is €7.33 (+24.87%).

Buy	19
Hold	15
Sell	4

News Go to news feed

Bausch Health launches Fraxel FTX laser system in Australia via Solta Medical

Bausch Health, through its aesthetics division Solta Medical, is introducing the Fraxel FTX laser system in Australia. The upgraded system uses two wavelengths (1927 nm for the epidermis, 1550 nm for the dermis), creates microscopic treatment zones and targets indications such as fine lines, wrinkles, acne scars, pigment lesions, as well as actinic keratosis and melasma. Innovations include a lighter handpiece, integrated cooling, AccuTRAC tracking and a modernized user interface; the device is prescription-only and will be supported by Solta Medical with clinical and hands-on training. » More on de.investing.com
Bausch Health falls to 52-week low of $4.56

Bausch Health shares closed at $4.56, marking a 52-week low and a one-year performance of -28.42%. Analysts nevertheless see upside and cite price targets between $6 and $9, while data from InvestingPro classify the stock as undervalued. Investors are watching the quarterly report due in eight days, seen as a potential turning point for the $1.75 billion pharmaceutical group. » More on de.investing.com
Bausch Health's PrOKEDI 75mg and 100mg listed in Quebec RAMQ formulary

Bausch Health Canada secured listing of PrOKEDI 75mg and 100mg dosages in the Régie de l'assurance maladie du Québec formulary, marking a key reimbursement milestone for the injectable risperidone treatment for adults with schizophrenia. PrOKEDI provides rapid therapeutic concentrations without oral supplementation or a loading dose and offers four-week dosing. The company said it will pursue coverage in other provinces following a prior Letter of Intent from the pan-Canadian Pharmaceutical Alliance to advance public drug program access. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2010, Bausch Health Companies has already paid €1.04 in dividends. The last payout was in December 2010.

Financials

In the last quarter, Bausch Health Companies had revenue of €2.5B and net profit of €226.06M

(EUR)	June 2026	YoY
Revenue	2.5B	16.42%
Gross profit	1.82B	21.64%
Net profit	226.06M	80.03%
EBITDA	898.12M	16.07%

Fundamentals

Metric	Value
Market capitalization	€2.15B
Number of shares	373.99M
52-week high/low	€6.90 - €3.74
Dividends	No
Beta	0.38
P/E ratio	-2.26
PEG ratio	0.00
P/B ratio	-1.41
P/S ratio	0.23

Company profile

Bausch Health Companies Inc. entwickelt, produziert und vermarktet zusammen mit seinen Tochtergesellschaften eine Reihe von pharmazeutischen Produkten, Medizinprodukten und rezeptfreien Produkten, vor allem in den therapeutischen Bereichen Augenheilkunde, Gastroenterologie und Dermatologie. Das Unternehmen ist in fünf Segmenten tätig: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics und Diversified Products. Das Segment Bausch + Lomb bietet Produkte mit den Schwerpunkten Sehhilfen, chirurgische und Verbraucherprodukte, chirurgische und ophthalmologische Arzneimittel an. Das Segment Salix bietet Produkte für die Gastroenterologie in den Vereinigten Staaten an. Das Segment International Rx bietet Solta-Produkte, pharmazeutische Markenprodukte und Generika, OTC-Produkte und medizintechnische Produkte sowie Produkte von Bausch + Lomb in Kanada, Europa, Asien, Australien, Lateinamerika, Afrika und dem Nahen Osten an. Das Segment Ortho Dermatologics bietet dermatologische Produkte in den Vereinigten Staaten und Solta medizinisch-ästhetische Geräte international an. Das Segment Diversified Products bietet pharmazeutische Produkte in den Bereichen Neurologie und andere therapeutische Klassen sowie Generika und zahnmedizinische Produkte in den Vereinigten Staaten an. Das Unternehmen war früher als Valeant Pharmaceuticals International, Inc. bekannt und änderte im Juli 2018 seinen Namen in Bausch Health Companies Inc. Der Hauptsitz von Bausch Health Companies Inc. befindet sich in Laval, Kanada.

Name	Bausch Health Companies
CEO	Thomas J. Appio
Headquarters	Laval, qc Canada
Website	bauschhealth.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	03/29/1994
Employees	20,300